Back to Search
JEAN GREM, MD
MD
Hematology & Oncology Physician
NPI: 1609824424IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
22376(NE)
CMS Specialties
PrimaryMEDICAL ONCOLOGY
Education
JEFFERSON MEDICAL COLLEGE OF THOMAS JEFFERSON UNIVERSITY
Class of 1980
Research & Publications (20)
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.
PMID 15774780·J Clin Oncol·2005
3-trial
Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer.
PMID 15726514·Semin Oncol·2005
6-review
Biochemical modulation of 5-FU in systemic treatment of advanced colorectal cancer.
PMID 11219972·Oncology (Williston Park)·2001
6-review
Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute's Anticancer Drug Screen.
PMID 11309351·Clin Cancer Res·2001
7-preclinical
Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion.
PMID 11269737·Cancer Chemother Pharmacol·2001
3-trial
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
PMID 11822758·Ann Oncol·2001
8-other
Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
PMID 11099325·J Clin Oncol·2000
3-trial
5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development.
PMID 11081567·Invest New Drugs·2000
6-review
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.
PMID 19124811·Ann Intern Med·2009
8-other
National Institutes of Health consensus development conference statement: management of hepatitis B.
PMID 19399804·Hepatology·2009
8-other
Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine.
PMID 19105824·BMC Cancer·2008
3-trial
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
PMID 18235115·J Clin Oncol·2008
3-trial
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
PMID 18235116·J Clin Oncol·2008
3-trial
Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function.
PMID 17699862·Clin Cancer Res·2007
8-other
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumors.
PMID 15930350·Clin Cancer Res·2005
3-trial
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer.
PMID 16168057·BMC Cancer·2005
3-trial
Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels.
PMID 16231011·Br J Pharmacol·2005
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 988102 NEBRASKA MEDICAL CTR
OMAHA, NE 68198 - Phone
- (402) 559-5600
Quick Facts
- NPI
- 1609824424
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 46
- Publications
- 20
Are you this provider?
Claim Your Profile